Project Grant R43HL178364
Award Date
4/20/25
Completion Date
3/31/27
Dollars Obligated
$414K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Unandup, LLC (KS8GMBKHNKV3)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
This $437,461 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of a novel stabilization catheter for His pacing lead implantation. The key product being developed is a sheath with a deployable suction flute that can improve the accuracy and ease of His lead placement for cardiac resynchronization therapy (CRT) in heart failure patients. The goal is to refine the sheath...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $310,170 to Cathpro Technologies, LLC to develop an innovative luminal insert for vascular catheters. The goal is to create a product that combines anti-infective and anti-thrombotic technologies to effectively reduce intraluminal infections and thrombotic occlusions in catheters. The funding will support feasibility studies to optimize...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $295,922 to Pericor LLC to develop a novel medical device called PERISCOPE. The device is designed to enable safer, fluoroscopy-free pericardial access for epicardial ablation procedures, which are essential but challenging steps in the treatment of over 300,000 cardiac ablation patients annually in the United States. The...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $134,151 to the University of California, Irvine to develop novel metasurface optical guidewires for therapeutic applications to treat previously untreatable highly stenotic coronary artery calcification (CAC) lesions. The objective is to design, develop, and manufacture metasurface optical guidewires that can provide precise...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $538,794 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Utah. The grant aims to develop a new magnetic resonance imaging (MRI) technology called Flow and Motion Insensitive Steady-State (FAMISS) to improve the detection of coronary artery disease (CAD) in patients with atrial fibrillation (AFib). The key products and services to be delivered under this 4-year grant include: (1)...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant of $1,283,558 to the Massachusetts Institute of Technology (MIT) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The purpose of this 4-year grant, with a start date of August 1, 2024, is to develop and demonstrate the concept of Multi-Electroplasmonic Nanoantenna Arrays (MENAS) - a breakthrough wireless technology for high-resolution, intracellular electrophysiological recording of...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $293,653 to 3DT Holdings, LLC to develop a software tool for optimizing cardiac resynchronization therapy (CRT), conduction system pacing (CSP), and left ventricular endocardial pacing (LVEP) therapies. The goal is to reduce non-responder rates and improve patient identification for these treatments, particularly for patients with...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,024,635 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Corvion, Inc. to develop a Totally Implanted Left Ventricular Assist Device (TI-LVAD). The TI-LVAD aims to reduce complications and improve quality of life for heart failure patients compared to current LVAD technologies which require a percutaneous driveline and external power supply. Key deliverables include finalizing the TI-LVAD design, developing the...
This $2,139,180 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to develop innovative MRI methods that can simultaneously and efficiently evaluate both the cardiac and respiratory systems in pediatric cardiopulmonary diseases. The key products and services to be delivered include: Free-running cardiopulmonary imaging techniques to provide anatomical imaging and quantification of ventilation, perfusion, cardiac function,...
The Project Grant R01HL169780 awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop a "4D Right-Heart Virtual Catheter (VCATH)" technology. This $691,326 project will create a rapid, non-invasive diagnostic tool that can comprehensively assess right heart hemodynamics using 4D flow MRI. The goal is to enable accurate diagnosis, differentiation, and prognosis of pulmonary hypertension (PH)...